Animal ID:
RC40104
|
Host:
Rabbit
|
Reactivity:
human
|
Buffers:
Purified rabbit polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column and eluted out with both high and low pH buffers and neutralized immediately after elution then followed by dialysis against PBS.
|
Storage:
Maintain refrigerated at 2-8ºC for up to 6 months. For long term storage store at -20ºC. Avoid repeated freeze-thaw cycles.
|
Application:
Tested by peptide-specific ELISA (1:1,000).
|
|
Immunogen:
N/A
|
Accession number:
NM_003921
|
Description:
B-cell CLL/lymphoma 10 (BCL10) was originally identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. BCL10 protein contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. By interacting with other CARD domain containing proteins including CARD9, 10, 11 and 14, BCL10 is thought to function as one of the upstream regulators in NF-kappaB signaling. Additionally, BCL10 is found to form a complex with MALT1, a protein known to be translocated in MALT lymphomas. MALT1 and BCL10 cooperate in the activation of NF-kappaB, and the deregulation of either one of them may contribute to the same pathogenetic process that leads to the malignancy.
|
Alternative Name(s):
CLAP, mE10, CIPER, c-E10, CARMEN, CARD-like apoptotic protein, CARD-containing proapoptotic protein, CARD containing molecule enhancing NF-kB, CARD-containing apoptotic signaling protein, caspase-recruiting domain-containing protein
|
References:
- Kawano T, Iwase S, Nakayama R, Horiguchi-Yamada J, Kobayashi M, Yamada H: Lack of BCL10 mRNA mutation in lymphold malignancies. Anticancer Res. 22(1A): 305-309 (2002).
- Bertoni F, Cavalli F, Cotter FE, Zucca E: Genetic alterations underlying the pathogenesis of MALT lymphoma. Hematol. J. 3(1): 10-13 (2002).
- Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, Merriam S, DiStefano PS, Alnemri ES: CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J. Biol. Chem. 276(15): 11877-11882 (2001). PMID: 11278692 [PubMed - indexed for MEDLINE]
- Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, Yamaoka S, Seto M, Nunez G: Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J. Biol. Chem. 276(22): 19012-19019 (2001).
- Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, Manji GA, Merriam S, Glucksmann MA, DiStefano PS, Alnemri ES, Bertin J: Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. J. Biol. Chem. 276(24): 21405-21409 (2001).
- Srinivasula SM, Ahmad M, Lin JH, Poyet JL, Fernandes-Alnemri T, Tsichlis PN, Alnemri ES: CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis. J. Biol. Chem. 274(25): 17946-17954 (1999).
- Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, Rakestraw KM, Naeve CW, Beckmann G, Weisenburger DD, Sanger WG, Nowotny H, Vesely M, Callet-Bauchu E, Salles G, Dixit VM, Rosenthal A, Schlegelberger B, Morris SW: Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat. Genet. 22(1): 63-68 (1999).
- Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ: Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96(1): 35-45 (1999).
|
For Research Use Only. Not for Diagnostic or Therapeutic Use.
Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Orbigen, Inc. is strictly prohibited
|
|
